Identifying skin cancer risk through discussions with healthcare providers and dermatologists allows for timely interventions ...

According to the latest study from BCC Research, the "Global Fluorescence Microscopy Market" is expected to grow from $968.5 ...

A team from Peking University’s College of Future Technology, led by Professor Xi Peng, in collaboration with Professor Jin Dayong at the Eastern Institute of Technology, has achieved a major ...

What if there were a fabric that, like Superman, could take a bullet and self-heal? Such a super-dynamic, action-powered ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist that is designed to reduce inflammation and pain in the eye.

"Life Sciences Drive Fluorescence Microscopy Market Growth Amid Rising Disease Prevalence and Technological Advances" BOSTON, April 30, 2025 /PRNewswire/ -- According to the latest study ...

This pilot study provides essential insights into how AI can augment traditional clinical workflows in diabetes management by ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

This valuable study provides insights into a key question in comparative neuroanatomy and development. The authors provide evidence of the role for a particular micro-RNA in regulating the development ...